News

Access Pharmaceuticals (Access) has provided an update on its North American commercial launch of MuGard, an FDA approved treatment for oral mucositis. Access plans to commercially launch MuGard

Millennium Laboratories has reported the company’s development and validation of a clinical quantitative assay for the new drug tapentadol (Nucynta) by liquid chromatography/tandem mass spectrometry (LC-MS/MS). In addition,

Amsterdam Molecular Therapeutics (AMT) has reported positive result of duchenne muscular dystrophy (DMD) in an animal model with its proprietary gene therapy. Reportedly, the proof of concept studies

Nutri-Force Nutrition has reported the completion of its new manufacturing facility in Miami Lakes, Florida. This new facility was designed from the ground up to provide Nutri-Force’s customers

Theratechnologies has presented the results from both its Phase 3 clinical trials evaluating Tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. In addition,

Duke University and Jubilant Organosys, through its subsidiary, Jubilant Biosys, have signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by

Opko Health has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co (Schering). Rolapitant, a neurokinin-1 (NK-1) receptor antagonist,

Vivakor has completed a distribution agreement with consumer product specialist, Regeneca International for one of its proprietary, nutraceutical formulations. In conjunction with this agreement was an immediate purchase

Nuvo Research’s German subsidiary Dimethaid has entered into a new licensing agreement with Ranbaxy for Oxoferin. The company has also reported an additional funding assistance, which willbe provided